News and Events

FH Canada registry Progress report 2016: English & French

Please find attached the Familial Hypercholesterolemia Canadian registry progress report for 2016. FH Canada registry Progress report 2016 15DEC2016 Registre HF Canada rapport de progres.

Support the FH Canada Patient Network

September 15, 2016   I am writing to you on behalf of the FH Canada Patient Network, a not-for-profit organization of patients and families living.

The Canadian Drug Expert Committee recommends that alirocumab be reimbursed. Alirocumab is approved by Health Canada as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or clinical atherosclerotic cardiovascular disease (CVC) who require additional lowering of low density lipoprotein cholesterol (LDL-C)

CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION: Common Drug Review CDEC Meeting — June 15, 2016  Notice of Final Recommendation — July 20, 2016 Alirocumab (Praluent –.

FH Canada invites you to Familial Hypercholesterolemia Canada Network Conferences will be given in French; Q&A in French and English